Krka Overview

  • Year Founded
  • 1954

Year Founded

  • Status
  • Public

  • Employees
  • 13,300

Employees

  • Stock Symbol
  • KRKG

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $276.81
  • (As of Thursday Closing)

Krka General Information

Description

Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.

Contact Information

Website
www.krka.biz
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Smarjeska cesta 6
  • Novo mesto, 8501
  • Slovenia
+386 068
Primary Industry
Pharmaceuticals
Stock Exchange
XLJU
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Smarjeska cesta 6
  • Novo mesto, 8501
  • Slovenia
+386 068

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Krka Stock Performance

As of 12-Nov-2026, Krka’s stock price is $276.81. Its current market cap is $8.38B with 30.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$276.81 $271.39 $224.98 - $311.17 $8.38B 30.3M 4.31K $16.05

Krka Financials Summary

As of 30-Jun-2026, Krka has a trailing 12-month revenue of $2.46B.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 7,857,029 6,618,136 3,897,970 3,197,733
Revenue 2,463,493 2,302,289 2,066,315 1,954,651
EBITDA 709,733 659,587 538,827 498,795
Net Income 487,199 454,853 386,294 339,713
Total Assets 3,801,011 3,573,963 2,964,611 3,055,647
Total Debt 21,046 21,567 13,685 13,264
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Krka Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Krka‘s full profile, request access.

Request a free trial

Krka Patents

  • 966

    Total Documents Applications and Grants

  • Total Patents Families

  • 274

    Granted

  • 44

    Pending

  • Expiring in next 12 mo

Krka Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4813462-A1 Salts of ribociclib having improved stability Pending 26-Mar-2025
WO-2026190263-A1 A combination for the treatment of hypertension Pending 14-Mar-2025
WO-2026153905-A1 Synthesis of vericiguat Pending 17-Jan-2025
EP-4775581-A2 Process for preparing finerenone Pending 14-Jan-2025
WO-2026139284-A1 Pharmaceutical dosage form comprising sertraline Pending 23-Dec-2024 A61K9/2077
To view Krka’s complete patent history, request access »

Krka Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Krka Investments & Acquisitions (4)

Krka’s most recent deal was a Joint Venture with Krka Pharma. The deal was made on 14-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Krka Pharma 14-Apr-2024 Joint Venture Pharmaceuticals
Ningbo Krka Menovo 05-Dec-2017 Joint Venture Therapeutic Devices
Alternova Arzneimittel 07-Nov-2008 Merger/Acquisition Drug Delivery
TAD Pharma 26-Nov-2007 Merger/Acquisition Pharmaceuticals
To view Krka’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Krka ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Krka’s complete esg history, request access »

Krka Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
TAD Pharma Cuxhaven, Germany 1968

Krka FAQs

  • When was Krka founded?

    Krka was founded in 1954.

  • Where is Krka headquartered?

    Krka is headquartered in Novo mesto, Slovenia.

  • What is the size of Krka?

    Krka has 13,300 total employees.

  • What industry is Krka in?

    Krka’s primary industry is Pharmaceuticals.

  • Is Krka a private or public company?

    Krka is a Public company.

  • What is Krka’s stock symbol?

    The ticker symbol for Krka is KRKG.

  • What is the current stock price of Krka?

    As of 12-Nov-2026 the stock price of Krka is $276.81.

  • What is the current market cap of Krka?

    The current market capitalization of Krka is $8.38B.

  • What is Krka’s current revenue?

    The trailing twelve month revenue for Krka is $2.46B.

  • What is Krka’s annual earnings per share (EPS)?

    Krka’s EPS for 12 months was $16.05.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process